Ann: Appointment of Dr Howie McKibbon as CEO, page-132

The April 2023 EH report suggests ~USD$1.7b after tax cash flow over 8 years (not sure why limited to 8yrs - I understood licensing was protected for 15 years), and is also only based on a maximum market penetration of 3% (by year 6). Japanese sales of Ecclock would indicate a bigger take-up, I suggest, and I think a market penetration of 6-10% instead is nowhere near unreasonable and would dramatically alter the figures.

Also, the EH report doesn't take into account the updated hundreds of millions saved in milestones and royalties with BOT's recent buyback.
I would understand that this report may be what the market is looking at which is holding back the price, but I suspect the market is in for a rude shock.

Encouragingly, EH are expected to provide refined numbers closer to commercial launch. As mentioned here before, they've already raised their target price from 28c to 33c - pre FDA approval.